AtriCure, Inc. (ATRC) is a prominent medical device company that provides innovative solutions designed to decrease the global epidemic of atrial fibrillation (AFib) and related conditions. The company is headquartered in Mason, Ohio, USA, and operates globally, providing relief and improved health to patients all over the world. AFib is a common cardiac disorder that increases the risk of stroke and cardiovascular diseases.
AtriCure, Inc.'s key product line includes ablation devices, a full solution for the surgical treatment of Afib and left atrial appendage management (LAAM). Their ablation technologies work by creating a line of scar tissue to block abnormal electric signals in the heart, restoring a regular heartbeat. The company's AtriClip Left Atrial Appendage Exclusion System product constitutes the most widely sold device worldwide for left atrial appendage management.
Established in 2000, AtriCure, Inc. has dedicated over two decades to developing and bringing to market a comprehensive suite of therapies aimed at rectifying the significant health issues attributed to AFib and other cardiac disorders. The company's commitment to research and education in the field of atrial fibrillation has set them apart as industry leaders.
In addition to technology, AtriCure, Inc. has made significant contributions to the field of education and training for healthcare professionals to create a broader understanding of the sources of AFib, as well as the surgical and hybrid procedural solutions.
As of now, over 200,000 patients with AFib have been treated with AtriCure technologies. Financially, AtriCure is a publicly traded company, listed on the NASDAQ Stock Market under the ticker ATRC.
In the face of a global epidemic of AFib, AtriCure, Inc. continues to innovate and contribute to enhanced patient care. They are fully committed to invest in clinical science, education, and training to ensure safe and effective treatment paving the way towards improved healthcare standards worldwide. Maintaining a steadfast dedication to quality, the company operates under a strict quality-focused system that meets the stringent needs of their medical device customers.
In conclusion, AtriCure, Inc. stands out as a pioneer, innovator, and leading-edge company in the fight against cardiac disorders such as AFib, enhancing the lives of patients and creating sustainable value for healthcare providers worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
AtriCure board member B. Kristine Johnson sold 2,452 shares of company stock for a total of $143,392 on November 10, according to an SEC filing. This insider transaction occurred while AtriCure shares were trading up by 0.81% at $56.72. The article also provides a detailed financial overview of AtriCure, highlighting its revenue growth, gross margin, EPS, debt management, and various valuation metrics.
AtriCure (NASDAQ: ATRC) reported strong third-quarter results, exceeding analyst expectations with earnings of 17 cents per share against an estimated loss of 5 cents, and sales of $154.450 million. Following these upbeat results, the company raised its FY2026 adjusted EPS guidance to 40 cents-46 cents per share and its sales guidance to $606.000 million-$610.000 million. BTIG and Needham analysts maintained their Buy ratings on AtriCure, both raising their price targets to $70, despite a slight pre-market dip in shares.